Advertisement

Conserved Cytotoxic Activity of Aclacinomycin A in Multifactorial Multidrug Resistance

  • R. Erttmann
  • A. Boetefür
  • K. D. Erttmann
  • F. Gieseler
  • G. Looft
  • M. Münchmeyer
  • A. Reymann
  • K. Winkler
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Identification of anthracyclines which are able to overcome multidrug resistance would be a major step towards to improving antineoplastic chemotherapy.

Keywords

Multi Drug Resistance Resistant Cell Line Cytostatic Drug Cytostatic Activity Small Cell Lung Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coley HM, Twentyman PR, Workman P (1990) 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer 26: 665–667PubMedCrossRefGoogle Scholar
  2. 2.
    Jensen PB, Vindelov L, Roed H, Demant EJF, Sehested M, Skovsgaard T, Hansen HH (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung ( SCCL ). Br J Cancer 60: 838–844PubMedCrossRefGoogle Scholar
  3. 3.
    Chen C, Chin J, Ueda K, Clark DP, Pastan I, Gottesmann MM, Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdrl (p-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389PubMedCrossRefGoogle Scholar
  4. 4.
    Gieseler F. Boege F, Clark M (1990) Alteration of Topoisomerase II action is a possible mechanism of HL-60 cell differentiation. Environ Health Perspect 88: 183–185PubMedCrossRefGoogle Scholar
  5. 5.
    Steinhoff A, Münchmeyer M, Looft G, Erttmann R (1989) Measurements of anthracycline accumulation in multidrug resistant and sensitive leukemia cells by fluorometry. Effect of verapamil and other membrane-transport modulating drugs. Naunyn Schmiedebergs Arch Pharmacol (Suppl) 339: R42Google Scholar
  6. 6.
    Reymann A, Edens L, Erb N, Erttmann R, Looft G, Woermann C (1989) Steady-state kinetics of anthracycline uptake in mouse Friend erythroleukemia cells. Naunyn Schmiedebergs Arch Pharmacol (Suppl) 340: R78Google Scholar
  7. 7.
    Weinstein RS, Kuszak JR, Kluskens LF, Coon JS (1990) P-glykoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21: 34–48PubMedCrossRefGoogle Scholar
  8. 8.
    Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1: 135–137PubMedCrossRefGoogle Scholar
  9. 9.
    Kemnitz J. Freund M, Dominis M, Cohnert TR, Uysal A, Georgii A (1989) Detection of cells with multidrug-resistant phenotype in myeloproliferative disorders before therapy. Hematol Pathol 3: 73–78PubMedGoogle Scholar
  10. 10.
    Holmes J, Jacobs A, Carter G, JanowskaWieczorek A, Padua RA (1989) Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72: 40–44PubMedCrossRefGoogle Scholar
  11. 11.
    Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S-Ig (1990) Expression of the multidrug transporter, p-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868–873PubMedCrossRefGoogle Scholar
  12. 12.
    Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo A (1989) Expression of the mdr-i/p-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388–1395PubMedGoogle Scholar
  13. 13.
    Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson I (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Nati Acad Sci USA 87: 7160–7164CrossRefGoogle Scholar
  14. 14.
    Tsuruo T (1988) Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 79: 285–296PubMedCrossRefGoogle Scholar
  15. 15.
    Zijlstra JG, de Vries EGE, Mulder NH (1987) Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780–1784PubMedGoogle Scholar
  16. 16.
    Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton Suttle DP, Trent JM (1987) Pharmacological, molecular and cytogenetic analysis of “atypical” multidrugresistant human leukemic cells. Cancer Res 47: 5455–5460PubMedGoogle Scholar
  17. 17.
    Mathe G, Gil M-A, Delgado M, Bayssas M, Gouevia J, Ribaud R, Machover D, Misset J-L, de Vassal F, Schwarzenberg L, Jasmin C, Hayat M (1980) Phase II trial in acute leukemia and lymphosarcoma. In: Mathe G, Muggia FM (eds) Cancer chemo-and immunopharmacology I. Springer, Berlin Heidelberg New York, pp 217–222 (Recent results in cancer research, vol 74 )Google Scholar
  18. 18.
    Pedersen-Bjeergard J, Brinker A, Ellegard J, et al. (1984) Aclarubicin in the treatment of acute non-lymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: phase II trial. Cancer Treat Rep 68: 1233–1238Google Scholar
  19. 19.
    Mitrou PS, Kuse R, Anger H, et al. (1985) Aclarubicin (Aclacinomycin A) in the treatment of relapsing acute leukaemias. Eur J Cancer Clin Oncol 21: 919–923PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Erttmann
    • 1
  • A. Boetefür
    • 1
  • K. D. Erttmann
    • 2
  • F. Gieseler
    • 3
  • G. Looft
    • 1
  • M. Münchmeyer
    • 1
  • A. Reymann
    • 4
  • K. Winkler
    • 1
  1. 1.Abteilung für Pädiatrische Hämatologie und OnkologieUniversitätskinderklinikHamburgGermany
  2. 2.Bernhard-Nocht-Institut für TropenmedizinHamburgGermany
  3. 3.Medizinische PoliklinikUniversität WürzburgWürzburgGermany
  4. 4.Abteilung für Allgemeine PharmakologiePharmakologisches Institut der UniversitätDeutschland

Personalised recommendations